Related Experiment Video
Updated: Mar 10, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease
The cholinergic system is dysfunctional in Huntington's disease (HD). Targeting this system offers novel therapeutic strategies for HD, with promising pre-clinical and clinical effects.
Area of Science:
- Neuroscience
- Neurodegenerative Diseases
- Pharmacology
Background:
- Huntington's disease (HD) is a fatal neurodegenerative disorder.
- Cholinergic system dysfunction is a hallmark of HD pathology.
- Evidence points to deficits in cholinergic transmission, neurons, receptors, and survival factors in HD.
Purpose of the Study:
- To review the role of the cholinergic system in Huntington's disease.
- To describe cholinergic system alterations in HD.
- To explore therapeutic strategies targeting the cholinergic system for HD.
Main Methods:
- Review of post-mortem human brain studies.
- Analysis of animal models of Huntington's disease.
- Examination of pre-clinical and clinical studies on cholinergic therapies.
Main Results:
- Significant dysfunction in cholinergic transmission, neurons, receptors, and survival factors in HD.
- Post-mortem and animal models confirm cholinergic deficits.
- Pre-clinical and clinical data suggest beneficial effects of cholinergic interventions.
Conclusions:
- The cholinergic system is a viable therapeutic target for Huntington's disease.
- Targeting cholinergic pathways may offer novel treatment avenues for HD.
- Cholinergic therapies show promise in ameliorating HD symptoms and progression.
More Related Videos
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...